Machine signal
Active cluster sell — 5 distinct insiders, $6.8M, window ends Aug 26, 2026.
Figures computed from official regulatory filings — .
Analysttarget 13.65 USD (+76%) · consensus 4.25/5 · 3 buy · 1 hold · 0 sell
Ownershipinsiders 12.64% · institutions 72.84% · short 21.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for PRECIGEN, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
307 buys228 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Thomasian Harry Jr.track record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| Thomasian Harry Jr.track record | Exercise | $100K | SEC |
| Thomasian Harry Jr.track record | Exercise | $50.7K | SEC |
| Thomasian Harry Jr.track record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thomasian Harry Jr.track record | Exercise | $1.9 | SEC |
| Thomasian Harry Jr.track record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thomasian Harry Jr.track record | Exercise | $1.2 | SEC |
| Thomasian Harry Jr.track record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KINDLER JEFFREY Btrack record | Sell | $1.4M | Unusual size | SEC |
| Shah Rutul R | Other | $26.3K | Unusual size | SEC |
| Shah Rutul R | Exercise | $80.8K | SEC |
| Tennant Phil | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Tennant Phil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shah Rutul R | Exercise | $35.7K | SEC |
| Shah Rutul R | Sell | $259.9K | SEC |
| Sabzevari Helen | Other | $73.3K | Unusual size | SEC |
| Shah Rutul R | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shah Rutul R | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Tennant Phil | Sell | $593.7K | SEC |
| Shah Rutul R | Sell | $115.1K | SEC |
| Tennant Phil | Exercise | $127.5K | SEC |
| Thomasian Harry Jr.track record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Lehr Donald P. | Other | $17.9K | SEC |
| Tennant Phil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shah Rutul R | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |